Shares Outstanding: 19.3m
Cash: 2.55m (+ $8m from Jan 28 offering)
Current liabilities: 537k
Current ratio: 6.72
NWC (total current assets - total current liabilities): 3.07m
Monthly Burn rate (net loss / months): 578k
Estimated current cash: 527k
Accumulated deficit: 38m
Book value (Stock holder equity / Shares outstanding): 0.223
-Receives FDA Fast track for its Oncorpex Immunogene therapy that targets lung cancer
-Sign Exclusive License Agreement with University of Pittsburgh for Potentially Curative Gene Therapy Candidate for Diabetes
-$25m shelf, recent offering 17/01/20 for $1.267m
-2020-01-28: Closes $8m offering
-Enough cash for 13 months
-Levels: 4.20, 4.70, 5, 5.40
First Test Long of 4.70 by 4.60 zone
Was not expecting a retracement to 4.50, tried to mitigate my loss when stock popped back into the 4.60s.
Execution detail:
Date/time | Symbol | Side | Price | Position |
---|---|---|---|---|
2020-02-18 10:01:35 | GNPX | buy | $4.720 | long |
2020-02-18 10:01:40 | GNPX | buy | $4.660 | long |
2020-02-18 10:01:40 | GNPX | buy | $4.680 | long |
2020-02-18 10:01:40 | GNPX | buy | $4.610 | long |
2020-02-18 10:04:04 | GNPX | sell | $4.630 | 0 |
You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes
just a few seconds to sign up, and it's free!